EXACTECH INC

EXACTECH INC specializes in the design, development, and manufacturing of orthopedic implant systems and surgical instrumentation, operating within the medical device manufacturing sector under NAICS 339113. The company’s core capabilities center on precision-engineered orthopedic solutions, including joint replacement systems, biocompatible implant materials, and minimally invasive surgical tools compliant with FDA 510(k) and ISO 13485 standards. Their technical expertise includes advanced biomaterials integration, CAD/CAM design for patient-specific instrumentation, and sterile packaging and validation protocols essential for clinical deployment. EXACTECH differentiates itself through proprietary implant geometries, enhanced fixation technologies, and rigorous quality control systems aligned with medical device lifecycle management requirements. Award history is not available to infer specific agency engagements or federal procurement patterns. As a commercial manufacturer without disclosed government certifications or federal contracting activity, there is no evidence of direct work with federal agencies such as the Department of Veterans Affairs, Defense Health Agency, or Public Health Service. The company’s industry focus is firmly rooted in medical device manufacturing, specifically orthopedic implants and surgical systems. This vertical involves high-regulation product development, regulatory submissions, and supply chain controls for healthcare providers and distributors. EXACTECH positions itself as a niche innovator in orthopedic biomechanics, serving hospitals, surgical centers, and private-sector healthcare networks rather than federal procurement channels. EXACTECH INC is a privately held, small business entity headquartered in Gainesville, Florida, with no publicly listed government certifications such as 8(a), HUBZone, or SDVOSB. The company operates primarily in the commercial medical device market, with no discernible footprint in federal contracting. Its market presence is defined by clinical partnerships and distributor networks rather than government procurement relationships.